Purpose: To evaluate MRI and histological concordance in prostate cancer (PCa) identification via mapped transperineal biopsies.
Methodology: Retrospective per-lesion analysis of patients undergoing MRI and transperineal biopsy at the Valencian Institute of Oncology (2016-2024) using CAPROSIVO PCa data. Patients underwent MRI, with or without regions of interest (ROI), followed by transperineal biopsies (3-5 cores/ROI, 20-30 systematic). Sensitivity (Se), specificity (Sp), negative predictive value (NPV), positive predictive value (PPV), and area under the curve (AUC) were calculated, considering PI-RADS 3 lesions as positive or negative. Gleason Grade Group (GG) > 1 defined clinically significant PCa (csPCa).
Results: 1817 lesions were analyzed from 1325 patients (median age 67, median PSA 6.3 ng/ml). 53% MRI were negative, GG > 1 prevalence was 29.1%. MRI-negative cases showed varying PCa rates: 57.4% negative, 34.3% GG 1, and 8.3% GG > 1. PI-RADS 3 lesions had mixed outcomes: 45.6% benign, 29.5% GG 1, and 24.9% GG > 1. 9.2% PI-RADS 4-5 lesions were negative, 23% GG 1, and 67.8% GG > 1. For PI-RADS 3 lesions considered positive, Se, Sp, NPV, PPV, and AUC were 84.9%, 68.4%, 91.7%, 52.6%, and 0.77 respectively. Considering PI-RADS 3 as negative yielded 70.6% Se, 86.2%, Sp, 87.7% NPV, 67.8% PPV, and 0.78 AUC.
Conclusion: MRI and mapped prostate biopsies exhibited moderate concordance. MRI could miss up to one in ten csPCa foci and misinterpret one in two ROIs. Careful MRI interpretation is crucial for optimizing patient care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00345-025-05534-3 | DOI Listing |
World J Urol
March 2025
Statistic Department, Valencia Instituto of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Purpose: To evaluate MRI and histological concordance in prostate cancer (PCa) identification via mapped transperineal biopsies.
Methodology: Retrospective per-lesion analysis of patients undergoing MRI and transperineal biopsy at the Valencian Institute of Oncology (2016-2024) using CAPROSIVO PCa data. Patients underwent MRI, with or without regions of interest (ROI), followed by transperineal biopsies (3-5 cores/ROI, 20-30 systematic).
Abdom Radiol (NY)
March 2025
Universidade de São Paulo, São Paulo, Brazil.
Objective: To prospectively determine the ability of visible lesions on multiparametric MRI (PI-RADS 4-5) and commonly used biomarkers to predict disease upgrading on rebiopsy in men with low-risk prostate cancer (PCa) enrolled in active surveillance (AS).
Materials And Methods: For this prospective study, approved by the Institutional Review Board (IRB), we selected consecutive patients with low-risk, low-grade, and localized prostate cancer (PCa) from our active surveillance (AS) program, who were enrolled between March 2014 and December 2020. Patients who had undergone previous prostate surgery, hormonal treatment, had contraindications for mpMRI, or transrectal ultrasound-guided (TRUS) biopsy were excluded from this study.
Eur J Nucl Med Mol Imaging
March 2025
Department of Medical Imaging, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is currently under evaluation for detecting clinically significant prostate cancer. The PSMA-PET/CT may complement the current standard diagnostic pathway for prostate cancer, which includes prostate-specific antigen (PSA) testing and multiparametric magnetic resonance imaging (mpMRI). This study evaluated the cost-effectiveness and quality of life impact of incorporating PSMA-PET/CT into this diagnostic algorithm.
View Article and Find Full Text PDFCurr Probl Diagn Radiol
March 2025
Department of Radiology, Urology and Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA. Electronic address:
Objective: To compare Prostate Imaging Reporting and Data System (PI-RADS) scores derived from a standard multiparametric prostate MRI (mpMRI) protocol with those from a protocol consisting only of T2-weighted and dynamic contrast-enhanced images (T2+DCE MRI).
Methods: In this retrospective, single-center, cross-sectional study approved by the IRB and compliant with HIPAA, 492 MRI exams performed in 2022 were analyzed. PI-RADS scores from mpMRIs were extracted from medical records, and new scores were generated for T2+DCE MRI following PI-RADS guidelines.
Ann Nucl Med
March 2025
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Objective: The aim of this study was to compare the diagnostic accuracy of Ga-PSMA-11 PET/CT and multiparametric MRI (mpMRI) in detecting unilateral and bilateral intra-glandular prostate cancer lesions.
Methods: A retrospective analysis was conducted on 73 prostate cancer patients diagnosed via biopsy, all of whom underwent both Ga-PSMA-11 PET/CT and mpMRI prior to surgery. Two independent readers, blinded to each other's results and to pathology findings, evaluated the imaging modalities to make a diagnosis of unilateral (left or right) or bilateral lesions for suspected prostate lesions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!